Asteroid: Regression of coronary atherosclerosis with rosuvastatin at a maximal daily dose of 40 mg;Asteroid: Régression de l'athérosclérose coronaire avec la rosuvastatine à une dose maximale de 40 mg par jour

Revue Medicale de Liege

Volumn 61, Issue 4, 2006, Pages 267-272

  Scheen, André J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Atherosclerosis; Cholesterol; Coronary heart disease; IVUS; Rosuvastatin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ATHEROMA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; INTRAVASCULAR ULTRASOUND; LIPOPROTEIN BLOOD LEVEL; MAXIMUM PERMISSIBLE DOSE; OUTCOME ASSESSMENT; REMISSION; REVIEW; UNSPECIFIED SIDE EFFECT; ARTICLE; BLOOD; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; FEMALE; MALE; MIDDLE AGED;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33745030405     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Libby P. - Changing concepts of atherogenesis. J Intern Med, 2000, 247, 349-358.
2. Scheen AJ.- Le risque cardio-vasculaire lié à l'hypercholestérolémie: d'un continuum à la notion de normalité, de seuil d'intervention et d'objectif thérapeutique. Rev Med Liège, 1999, 54, 17-21.
3. Baigent C, Keech A, Kearney PM, et al.- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366, 1267-1278.
4. Scheen AJ.- Treating to New Targets: plaidoyer pour une valeur cible de cholestérol LDL égale ou inférieure à 75 mg/dl chez tout patient coronarien. Rev Med Liège, 2005, 60, 264-267.
5. Scheen AJ.- L'étude IDEAL comparant simvastatine 20-40 mg versus atorvastatine 80 mg en prévention après un infarctus du myocarde: entre deux idées de l'idéal. Rev Med Liège, 2006, 61, 53-59.
6. Carswell CI, Plosker GL, Jarvis B.- Rosuvastatin. Drugs, 2002, 62, 2075-85.
7. Scheen AJ.- Rosuvastatine (Crestor®). Rev Med Liège, 2004, 59, 56-59.
8. Jones PH, Davidson MH, Stein EA, et al, for the STELLAR Study Group.- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol, 2003, 93, 152-160.
9. Stender S, Schuster H, Barter P, et al.- Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab, 2005, 7, 430-438.
10. Schuster H, Fox JC.- Investigating cardiovascular risk reduction: the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother, 2004, 5, 1187-1200.
11. Scheen AJ.- Comment j'explore ... les critères de jugement dans les essais cliniques: réflexion à propos d'études récentes de prévention cardio-vasculaire. Rev Med Liège, 2006, 61, 260-266
12. Taylor A, Shaw LJ, Fayad Z, et al.- Tracking atherosclerosis regression: a clinical tool in preventive cardiology. Atherosclerosis, 2005, 180, 1-10.
13. Nissen SE, Yock P.- Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation, 2001, 103, 604-616.
14. Nissen SE, Nicholls SJ, Sipahi I, et al.- Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA, 2006, 295, online March 13 (doi:10.1001/jama.295.13.jpc60002).
15. MAAS Study Group. - Effect of simvastatin on coronary atheroma: the Multicentre Anti-athetroma Study (MAAS). Lancet, 1994, 344, 633-638.
16. Nissen SE, Tuzcu EM, Schoenhagen P, et al.- Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomised controlled trial. JAMA, 2004, 291, 1071-1080.
17. Blumenthal R, Kapur NK.- Can a potent statin actually regress coronary athetosclerosis? JAMA, 2006, 295, online March 13 (doi:10.1001/jama.295.13. jpc60002).
18. Scheen AJ, Kulbertus H.- "REVERSAL" et "PROVE-IT": confirmation du concept «the lower, the better» dans le traitement de l'hypercholestérolémie chez le patient coronarien. Rev Med Liège, 2004, 59, 167-173.
19. Nissen SE, Tsunoda T, Tuzcu EM, et al.- Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA, 2003, 290, 2292-2300.
20. Grobbee DE, Bots ML.- Atherosclerotic disease regression with statins: studies using vascular markers. Int J Cardiol, 2004, 96, 447-459.
21. Scheen AJ, Kulbertus H. - Prévention cardio-vasculaire par les statines: faut-il encore doser le cholestérol? Rev Med Liège, 2003, 58, 191-197.
22. Bonetti PO, Lerman LO, Napoli C, Lerman A.- Statin effects beyond lipid lowering are they clinically relevant? Eur Mean J, 2003, 24, 225-248.
23. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol, 2002, 40, 567-572.
24. Scheen AJ.- Pharmaco-économie des médicaments hypolipidémiants: analyse des facteurs influençant le rapport coût/efficacité. Rev Med Liège, 1998, 53, 220-222.